Orally administered recombinant Lactobacillus casei vector vaccine expressing β-toxoid of Clostridium perfringens that induced protective immunity responses

Clostridium perfringens types B and C cause enteritis and enterotoxemia in animals. The conventional vaccine production systems need time-consuming detoxification and difficult quality control steps. In this study, a modified beta-toxoid gene was synthesized, cloned into the pT1NX vector, and electroporated into Lactobacillus casei competent cells to yield L. casei-beta recombinant strain. Surface expression of the recombinant beta-toxoid was evaluated by ELISA and confirmed by immunofluorescence microscopy. Vaccinated BALB/c mice with L. casei-beta induced potent humoral and cell-mediated immune responses that were protective against lethal challenges with 100 MLD/mL of the beta-toxin. Safety and efficacy of the recombinant clone was evaluated and the presumptive toxicity of L. casei-beta was studied by toxicity test and histopathological findings, which were the same as negative controls. Our results support the use of L. casei as a live oral vector vaccine, and that the recombinant L. casei-beta is a potential candidate for being used in the control of enterotoxemia diseases caused by C. perfringens types B and C.